Last reviewed · How we verify
Mitomycin and doxifluridine
Mitomycin and doxifluridine work synergistically as a chemotherapy combination, with mitomycin acting as an alkylating agent and doxifluridine as a fluoropyrimidine antimetabolite to inhibit DNA synthesis and induce cancer cell death.
Mitomycin and doxifluridine work synergistically as a chemotherapy combination, with mitomycin acting as an alkylating agent and doxifluridine as a fluoropyrimidine antimetabolite to inhibit DNA synthesis and induce cancer cell death. Used for Gastric cancer (Phase 3 development).
At a glance
| Generic name | Mitomycin and doxifluridine |
|---|---|
| Sponsor | Asan Medical Center |
| Drug class | Chemotherapy combination (alkylating agent + fluoropyrimidine antimetabolite) |
| Target | DNA (mitomycin); thymidylate synthase and nucleotide metabolism (doxifluridine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Mitomycin is a mitomycin C derivative that functions as a DNA cross-linking agent, creating interstrand DNA adducts that prevent replication and transcription. Doxifluridine is a prodrug of 5-fluorouracil that inhibits thymidylate synthase and incorporates into RNA and DNA, disrupting nucleotide synthesis. The combination targets rapidly dividing cancer cells through complementary mechanisms of DNA damage and antimetabolite activity.
Approved indications
- Gastric cancer (Phase 3 development)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Diarrhea
- Mucositis
- Anemia
- Hepatotoxicity
Key clinical trials
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
- Trial of Adjuvant Chemotherapy for Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitomycin and doxifluridine CI brief — competitive landscape report
- Mitomycin and doxifluridine updates RSS · CI watch RSS
- Asan Medical Center portfolio CI